Terlipressin Hrs denied as not medically necessary by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Terlipressin for Medical Necessity — and How to Overturn It

Terlipressin is FDA-approved for hepatorenal syndrome type 1 (HRS-1), a rapidly progressive and potentially fatal complication of cirrhosis. A medical-necessity denial from Humana means the plan's reviewer concluded that the clinical documentation submitted did not demonstrate that terlipressin is medically required for this patient at this time — even if the diagnosis is acknowledged.

### Why This Denial Happens

Humana applies clinical coverage criteria that typically mirror the FDA label's indication requirements plus additional payer-defined thresholds. Medical-necessity denials most often occur because (1) the documentation sent with the prior-authorization request was incomplete, (2) the specific lab values or clinical findings needed to satisfy each criterion were not explicitly stated, or (3) a required step — such as prior treatment with a specified agent — was not documented in the records.

### Why It's Appealable

Medical-necessity determinations are judgment calls, and judgments can be reversed when the clinical record is fully presented. Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review by a physician who was not involved in the original denial. You then have the right to independent external review if the internal appeal fails. File the external-review request within approximately four months of the denial notice. For an acutely ill, hospitalized patient with HRS-1, expedited review (72-hour decision) is available.

### Concrete Appeal Process

1. Obtain Humana's clinical criteria — Request the specific medical-necessity policy applied to terlipressin for HRS-1 in writing. 2. Gap analysis — Compare each criterion against the records already submitted; identify every gap. 3. Internal appeal — Re-submit with a complete documentation package (see below) and a prescriber letter that addresses each criterion explicitly. 4. External review — If the internal appeal is denied, request independent review; an independent hepatologist or intensivist reviewer is likely to weigh the clinical urgency of HRS-1 heavily.

### Documentation to Gather

• Diagnosis confirmation — full hepatologist or gastroenterologist chart notes documenting the HRS-1 diagnosis, consistent with the criteria described in the FDA-approved prescribing information and current AASLD guidelines.
• Prior-treatment history — dates, durations, doses, and documented outcomes or reasons for inadequacy of any treatments Humana's policy requires before terlipressin.
• Clinical severity — objective findings from the chart (laboratory trends, clinical status scores, organ-function trajectory) recorded by the treating team.
• Prescriber medical-necessity letter — a detailed, criterion-by-criterion letter from the treating hepatologist or hospitalist explaining how this patient meets each of Humana's published requirements and citing the applicable professional guideline.

### Criteria-Mapping Structure

Print Humana's published coverage policy and the FDA prescribing label side by side. For every criterion listed — diagnosis, disease severity, prior treatment, monitoring requirements — write the exact chart fact that satisfies it, with the date and source document. Submit this mapping as a structured exhibit with your appeal letter. Reviewers are more likely to approve when they do not have to search for supporting facts; present the complete picture in one organized document.